文献速递头颈部肿瘤放疗

纳武利尤单抗加入中高危局部晚期头颈部鳞癌放化疗平台的安全性:RTOG Foundation 3504

Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-10-11

本研究评估纳武利尤单抗联合同步70 Gy调强放疗及四种方案(每周顺铂、每3周顺铂、西妥昔单抗、或不含铂)治疗新诊断中高危局部晚期头颈部鳞癌的安全性。39例患者中,第1、2组无剂量限制性毒性,第3组1例(黏膜炎),第4组2例(脂肪酶升高和黏膜炎1例、乏力1例);辅助纳武利尤单抗按方案定义可行。

要点

  • 纳武利尤单抗联合同步70 Gy调强放疗及四种方案在中高危头颈部鳞癌中安全。
  • 第1、2组无剂量限制性毒性,第3组1例黏膜炎,第4组2例(脂肪酶升高和黏膜炎1例、乏力1例)。
  • 辅助纳武利尤单抗至1年按方案定义(前8例可评估患者中≥4例接受全部7次额外剂量)可行。

核心结论

  • 纳武利尤单抗联合同步四种放化疗方案对中高危头颈部鳞癌患者安全,后续辅助纳武利尤单抗按定义可行。

研究设计与样本

  • 研究纳入39例新诊断中高危局部晚期头颈部鳞癌患者,第1组10例、第2组9例、第3组10例、第4组10例。
  • 患者接受纳武利尤单抗联合同步70 Gy调强放疗及每周顺铂(第1组)、每3周顺铂(第2组)、西妥昔单抗(第3组)或不含铂(第4组,铂类不耐受患者)。
  • 纳武利尤单抗从放疗前2周开始至放疗后3个月;主要终点为剂量限制性毒性(DLT),若前8例可评估患者中≤2例发生DLT则该组认为安全。

主要发现

  • 39例患者中72%为T3-4肿瘤,85%为N2-3淋巴结病变,67%吸烟>10包年。
  • 第1组和第2组无DLT,第3组1例(黏膜炎),第4组2例(脂肪酶升高和黏膜炎1例、乏力1例)。
  • 最常见的≥3级纳武利尤单抗相关不良事件为脂肪酶升高、黏膜炎、腹泻、淋巴细胞减少、低钠血症、白细胞减少、乏力和血清淀粉酶升高。
  • 辅助纳武利尤单抗按方案定义可行(前8例可评估患者中≥4例接受全部7次额外剂量)。

关键数值与推荐

  • 主要终点DLT判定标准:前8例可评估患者中≤2例发生DLT则该组安全;第1组0例、第2组0例、第3组1例、第4组2例。
  • 辅助纳武利尤单抗可行性定义:前8例可评估患者中≥4例接受全部7次额外剂量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Programmed death-1 immune checkpoint blockade improves survival of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but the benefits of addition to (chemo)radiation for newly diagnosed patients with HNSCC remain unknown. METHODS AND MATERIALS: We evaluated the safety of nivolumab concomitant with 70 Gy intensity modulated radiation therapy and weekly cisplatin (arm 1), every 3-week cisplatin (arm 2), cetuximab (arm 3), or alone for platinum-ineligible patients (arm 4) in newly diagnosed intermediate- or high-risk locoregionally advanced HNSCC. Patients received nivolumab from 2 weeks prior to radiation therapy until 3 months post-radiation therapy. The primary endpoint was dose-limiting toxicity (DLT). If ≤2 of the first 8 evaluable patients experienced a DLT, an arm was considered safe. Secondary endpoints included toxicity and feasibility of adjuvant nivolumab to 1 year, defined as all 7 additional doses received by ≥4 of the first 8 evaluable patients across arms. RESULTS: Of 39 patients (10 in arms 1, 3, 4 and 9 in arm 2), 72% had T3-4 tumors, 85% had N2-3 nodal disease, and 67% had >10 pack-years of smoking. There were no DLTs in arms 1 and 2, 1 in arm 3 (mucositis), and 2 in arm 4 (lipase elevation and mucositis in 1 and fatigue in another). The most common grade ≥3 nivolumab-related adverse events were lipase increase, mucositis, diarrhea, lymphopenia, hyponatremia, leukopenia, fatigue, and serum amylase increase. Adjuvant nivolumab was feasible as defined in the protocol. CONCLUSIONS: Concomitant nivolumab with the 4 tested regimens was safe for patients with intermediate- and high-risk HNSCC, and subsequent adjuvant nivolumab was feasible as defined (NCT02764593).

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gillison ML, Ferris RL, Harris J, et al. Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504. Int J Radiat Oncol Biol Phys. 2022. PMID: 36228746. doi:10.1016/j.ijrobp.2022.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。